Evercore ISI Group Maintains In-Line on Guardant Health, Lowers Price Target to $90

Evercore ISI Group analyst Daniel Markowitz maintains Guardant Health (NASDAQ:GH) with a In-Line and lowers the price target from $110 to $90.